Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer

Cancer Research

Volumn 59, Issue 18, 1999, Pages 4662-4667

  Fullwood, Paul ^a   Marchini, Sergio ^b   Rader, Janet S ^c   Martinez, Alonso ^a   Macartney, Donia ^a   Broggini, Massimo ^b   Morelli, Cristina ^d   Barbanti Brodano, Giuseppe ^d   Maher, Eamonn R ^a   Latif, Farida ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b Molecular Pharmacology Unit   (Italy)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MICROSATELLITE DNA;

ARTICLE; CANCER STAGING; CHROMOSOME 3P; CHROMOSOME MAP; CONTROLLED STUDY; DNA DETERMINATION; GENE LOCATION; GENE LOCUS; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MARKER GENE; MICROSATELLITE INSTABILITY; OVARY CARCINOMA; PEPTIDE MAPPING; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ACID ANHYDRIDE HYDROLASES; CHROMOSOME MAPPING; CHROMOSOMES, ARTIFICIAL, YEAST; CHROMOSOMES, HUMAN, PAIR 3; FEMALE; GENES, TUMOR SUPPRESSOR; GENETIC MARKERS; HUMANS; LOSS OF HETEROZYGOSITY; NEOPLASM PROTEINS; NEOPLASM STAGING; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROTEINS;

EID: 0033567894     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Skolnick, M. H., Frank, T., Shattuck-Eidens, D., and Tavtigian, S. Genetic susceptibility to breast and ovarian cancer. Pathol. Biol., 45: 245-249, 1997.
2. Angioli, R., Estape, R., Mason, M., and Penalver, M. Hereditary and sporadic ovarian cancer: genetic testing and clinical implications. Int. J. Oncol., 12: 1029-1034, 1998.
3. Sato, T., Saito, H., Morita, R., Koi, S., Lee, H., and Nakamura, Y. Allelotype of human ovarian cancer. Cancer Res., 51: 5118-5122, 1991.
4. Zheng, J. P., Robinson, W. R., Ehlen, T., Yu, M. C., and Dubeau, L. Distinction of low grade from high grade human ovarian carcinomas on the basis of losses of heterozygosity on chromosomes 3, 6, and 11 and HER-2/neu gene amplification. Cancer Res., 51: 4045-4051, 1991.
5. Dodson, M. K., Hartmann, L. C., Cliby, W. A., DeLacey, K. A., Keeney, G. L., Ritland, S. R., Su, J. Q., Podralz, K. C., and Jenkins, R. B. Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas. Cancer Res., 53: 4456-4460, 1993.
6. Yang-Feng, T. L., Han, H., Chen, K. C., Li, S. B., Claus, E. B., Carcangiu, M. L., Chambers, S. K., Chambers, J. T., and Schwartz, P. E. Allelic loss in ovarian cancer. Int. J. Cancer, 54: 546-551, 1993.
7. Foster, K., Osborne, R. J., Huddart, R. A., Affara, N. A., Ferguson-Smith, M. A., and Maber, E. R. Molecular genetic analysis of the von Hippel Lindau disease (VHL) tumour suppressor gene in gonadal tumors. Eur. J. Cancer, 31A: 2392-2395, 1995.
8. Lounis, H., Mes-Masson, A. M., Dion, F., Bradley, W. E., Seymour, R. J., Provencher, D., and Tonin, P. N. Mapping of chromosome 3p deletions in human epithelial ovarian tumors. Oncogene, 17: 2359-2365, 1998.
9. Kok, K., Naylor, S. L., and Buys, C. H. Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes. Adv. Cancer Res., 71: 27-92, 1997.
10. Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F. M., Orcutt, M. L., Stackhouse, T., Kuzmin, I., Modi, W., Geil, L., Schmidt, L., Zhou, F., Li, H., Wei, M., Chen, F., Glenn, G., Choyke, P., Walther, M. M., Weng, Y., Duan, S. R., Dean, M., Glavac, D., Richards, F. M., Crossey, P. A., Ferguson-Smith, M. A., Le Paslier, D., Chumakov, I., Cohen, D., Chinault, A. C., Maher, E. R., Linehan, W. M., Zbar, B., and Lerman, M. I. Identification of the von Nippel-Lindau disease tumor suppressor gene. Science (Washington DC), 260: 1317-1320, 1993.
11. Crossey, P. A., Richards, F. M., Foster, K., Green, J. S., Prowse, A., Latif, F., Lerman, M. I., Zbar, B., Affara, N. A., Ferguson-Smith, M. A., and Maher, E. R. Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum. Mol. Genet., 3: 1303-1308, 1994.
12. Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M., Li, H., Latif, F., Lie, S., Chen, F., Duh, F. M., Lubensky, I., Duan, D., Florence, C., Pozzatti, R., Walther, M. M., Bander, N. H., Grossman, H. B., Brauch, H., Pomer, S., Brooks, J. D., Isaac, W. B., Lerman, M. I., Zbar, B., and Linehan, W. M. Mutation of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet., 7: 85-90, 1994.
13. Foster, K., Prowse, A., van den Berg, A., Fleming, S., Hulsbeek, M. M., Crossey, P. A., Richards, F. M., Cairns, P., Affara, N. A., Ferguson-Smith, M. A., Buys, C. H. C. M., and Maher, E. R. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum. Mol. Genet., 3: 2169-2173, 1994.
14. Kaelin, W. G., Jr., and Maher, E. R. The VHL tumour-suppressor gene paradigm. Trends Genet., 14: 423-426, 1998.
15. Sekido, Y., Ahmadian, M., Wistuba, I. I., Latif, F., Bader, S., Wei, M. H., Duh, F. M., Gazdar, A. F., Lerman, M. I., and Minna, J. D. Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene. Oncogene, 16: 3151-3157, 1998.
16. Wei, M. H., Latif, F., Bader, S., Kashuba, V., Chen, J. Y., Duh, F. M., Sekido, Y., Lee, C. C., Geil, L., Kuzmin, I., Zabarovsky, E., Klein, G., Zbar, B., Minna, J. D., and Lerman, M. I. Construction of a 600-kb cosmid clone contig and generation of a transcriptional map surrounding the lung cancer tumor suppressor gene (TSG) locus on human chromosome 3p21.3. Cancer Res., 56: 1487-1492, 1996.
17. Rabbitts, P., Bergh, J., Douglas, J., Collins, F., and Waters, J. A submicroscopic homozygous deletion at the D3S3 locus in a cell line isolated from a small cell lung carcinoma. Genes Chromosomes Cancer, 2: 231-238, 1990.
18. Latif, F., Tory, K., Modi, W. S., Graziano, S. L., Gamble, G., Douglas, J., Heppell-Parton, A. C., Rabbitts, P. H., Zbar, B., and Lerman, M. I. Molecular characterization of a large homozygous deletion in the small cell lung cancer cell line U2020: a strategy for cloning the putative tumor suppressor gene. Genes Chromosomes Cancer, 5: 119-127, 1992.
19. Sundaresan, V., Chung, G., Heppell-Parton, A., Xiong, J., Grundy, C., Roberts, I., James, L., Cahn, A., Bench, A., Douglas, J., Minna, J., Sekido, Y., Lerman, M., Latif, F., Bergh, J., Li, H., Lowe, N., Ogilvie, D., and Rabbitts, P. Homozygous deletions at 3p12 in breast and lung cancer. Oncogene, 17: 1723-1729, 1998.
20. Ohta, M., Inoue, H., Omicelli, M. G., Kastury, K., Baffa, R., Palazzo, J., Siprashvili, Z., Mori, M., McCue, P., Druck, T., Croce, C. M., and Huebner, K. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell, 84: 587-597, 1996.
21. Sozzi, G., Veronese, M. L., Negrini, M., Baffa, R., Cotticelli, M. G., Inoue, H., Tomielli, S., Pilotti, S., De Gregorio, L., Pastorino, U., Pierotti, M. A., Ohta, M., Huebner, K., and Croce, C. M. The FHIT gene 3p14.2 is abnormal in lung cancer. Cell, 85: 17-26, 1996.
22. Sozzi, G., Alder, H., Tornielli, S., Corletto, V., Baffa, R., Veronese, M. L., Negrini, M., Pilotti, S., Pierotti, M A., Huebner, K., and Croce, C. M. Aberrant FHIT transcripts in Merkel cell carcinoma. Cancer Res., 56: 2472-2474, 1996.
23. Virgilio, L., Shuster, M., Gollin, S. M., Veronese, M. L., Ohta, M., Huebner, K., and Croce, C. M. FHlT gene alterations in head and neck squamous cell carcinomas. Proc. Natl. Acad. Sci. USA, 93: 9770-9775, 1996.
24. Hendricks, D. T., Taylor, R., Reed, M., and Birrer, M. J. FHIT gene expression in human ovarian, endometrial, and cervical cancer cell lines. Cancer Res., 57: 2112-2115, 1997.
25. Huebner, K., Hadaczek, P., Siprashvili, Z., Druck, T., and Croce, C. M. The FHIT gene, a multiple tumor suppressor gene encompassing the carcinogen sensitive chromosome fragile site, FRA3B. Biochim. Biophys. Acta, 1332: M65-M70, 1997.
26. Rimessi, P., Gualandi, F., Morelli, C., Trabanelli, C., Wu, Q., Possati, L., Montesi, M., Barrett, J. C., and Barbanti Brodano, G. Transfer of human chromosome 3 to an ovarian carcinoma cell line identifies three regions on 3p involved in ovarian cancer. Oncogene, 9: 3467-3474, 1994.
27. Emmert-Buck, M. R., Bonner, R. F., Smith, P. D., Chuaqui, R. F., Zhuang, Z., Goldstein, S. R., Weiss, R. A., and Liotta, L. A. Laser capture microdissection. Science (Washington DC), 274; 998-1001, 1996.
28. Lui, W., Piechocki, M., Shridhar, V., Lytes, G., Song, Z., Nakamura, Y., Drabkin, H., Vance, J., and Smith, D. I. The isolation of a yeast artificial chromosome (YAC) contig extending for 2 megabases in the vicinity of the von Hippel-Lindau disease gene. Hum. Mol. Genet., 2: 1177-1182, 1993.
29. Lott, S. T., Lovell, M., Naylor, S. L., and Killary, A. M. Physical and functional mapping of a tumor suppressor locus for renal cell carcinoma within chromosome 3p12. Cancer Res., 58: 3533-3537, 1998.
30. Lynch, M. A., Nakashima, R., Song, H., DeGroff, V. L., Wang, D., Enomoto, T., and Weghorst, C. M. Mutational analysis of the transforming growth factor ßreceptor type II gene in human ovarian carcinoma. Cancer Res., 58: 4227-4232, 1998.
31. van den Berg, A., Dijkhuizen, T., Draaijers, T. G., Hulsbeek, M. M., Maher, E. R., van den Berg, E., Storkel, S., and Buys, C. H. C. M. Analysis of multiple renal cell adenomas and carcinomas suggests allelic loss at 3p21 to be a prerequisite for malignant development. Genes Chromosomes Cancer, 19: 228-232, 1997.
32. Clifford, S. C., Prowse, A. H., Affara, N. A., Buys, C. H., and Maher, E. R. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer, 22: 200-209, 1998.
33. Chung, G. T., Sundaresan, V., Hasleton, P., Rudd, R., Taylor, R., and Rabbitts, P. H. Sequential molecular genetic changes in lung cancer development. Oncogene, 11: 2591-2598, 1995.